The COVID‑19 crisis made mRNA vaccines famous worldwide. After testing, the first mRNA shot was given on December 8, 2020, and models say it saved millions of lives in the first year.
Because they worked well, scientists started testing mRNA vaccines for other germs such as flu, RSV, HIV, Zika, Epstein‑Barr, and tuberculosis. Yet, studies also showed limits that push researchers to look for new ways.
Why mRNA Shots Face Problems
Protection from mRNA vaccines can vary a lot between people and can fade over time. The virus that causes COVID‑19 keeps changing, making old shots less effective. This means vaccines must be updated often.
Making mRNA vaccines is also tricky and costly. It is hard to control how many mRNA strands go into each tiny fat bubble (lipid nanoparticle). The shots need very cold storage and can sometimes affect parts of the body they were not meant for.
DNA Origami: A New Vaccine Idea
To solve these issues, scientists at the Wyss Institute, Dana‑Farber Cancer Institute, and partners built a new platform called DoriVac. It uses DNA origami – tiny, folded DNA shapes – as both the vaccine carrier and its own booster.
They designed DoriVac to show a small protein piece (called HR2) that appears on the spikes of several viruses, including SARS‑CoV‑2, HIV, and Ebola. In mouse tests, the HR2 version sparked strong antibody and T‑cell responses.
The team also used a “human lymph node‑on‑a‑chip” that mimics a real human lymph node. In this device, the same DNA‑origami vaccine produced clear immune signals from human cells.
When they compared DoriVac to a standard mRNA vaccine carrying the same spike piece, both gave similar immune strength. However, the DNA‑origami shot was more stable, easier to store, and simpler to make.
How the DNA Origami Vaccine Is Made
DoriVac is built from tiny square DNA tiles that snap together on their own. One side of each tile holds immune‑boosting molecules placed at exact distances. The opposite side displays chosen virus parts or tumor proteins.
Earlier experiments in tumor‑bearing mice showed that the DNA‑origami structure made the immune system react louder than plain proteins without the DNA frame.
Scientists observed far more antibody‑producing B cells, active dendritic cells, and memory or killer T cells when using DoriVac, especially with the SARS‑CoV‑2 HR2 piece.
Testing in Human‑Like Models
Mouse results do not always match human outcomes, which is why many promising drugs fail later. To bridge this gap, researchers used a human lymph‑node‑chip that reproduces key parts of the human immune response.
The chip confirmed that DoriVac can trigger the same strong, virus‑specific immunity seen in mouse studies.
Side‑by‑Side With mRNA Shots
In a standard booster experiment with mice, both the DNA‑origami and mRNA vaccines gave similar levels of antiviral T cells and antibody‑making B cells.
Beyond similar effectiveness, DoriVac avoids the strict cold‑chain needs of mRNA vaccines, making it easier to ship to places without advanced refrigeration. It also skips many complicated steps needed to pack mRNA into lipid bubbles, cutting production time and cost.
Recent safety tests show that DoriVac is well tolerated, adding confidence that this approach could move forward into human trials.